Can we afford to eliminate restenosis?: Can we afford not to?

Journal of the American College of Cardiology

Volumn 43, Issue 4, 2004, Pages 513-518

  Greenberg, Dan ^a,b   Bakhai, Ameet ^a,b,c   Cohen, David J ^a,b  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Bare metal stent(s); Coronary artery bypass graft surgery; Coronary artery disease; Diagnosis related group; Drug eluting stent(s); Percutaneous coronary intervention; Quality of life; Quality adjusted life year; Target vessel revascularization

Indexed keywords

RAPAMYCIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DIAGNOSIS RELATED GROUP; DRUG COST; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ECONOMIC ASPECT; ECONOMICS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; INCIDENCE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; STENT; UNITED STATES;

EID: 1242340310     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.020     Document Type: Review

References (34)

1. Gruntzig A.R., Senning A., Siegenthaler W.E. Nonoperative dilatation of coronary-artery stenosis percutaneous transluminal coronary angioplasty . N Engl J Med. 301:1979;61-68.
2. Williams D.O., Holubkov R., Yeh W., et al. Percutaneous coronary intervention in the current era compared with 1985-1986 the National Heart, Lung, and Blood Institute Registries . Circulation. 102:2000;2945-2951.
3. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
4. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
5. Serruys P.W., van Hout B., Bonnier H., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet. 352:1998;673-681.
6. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis classification and implications for long-term outcome . Circulation. 100:1999;1872-1878.
7. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780.
8. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 349:2003;1315-1323.
9. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries double-blind, randomised controlled trial (E-SIRIUS) . Lancet. 362:2003;1093-1099.
10. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions . Circulation. 107:2003;38-42.
11. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 348:2003;1537-1545.
12. O'Neill W.W., Leon M.B. Drug-eluting stents costs versus clinical benefit . Circulation. 107:2003;3008-3011.
13. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 344:2001;1117-1124.
14. Pocock S.J., Henderson R.A., Rickards A.F., et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet. 346:1995;1184-1189.
15. Weintraub W.S., Ghazzal Z.M., Douglas J.S. Jr., et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 87:1993;831-840.
16. Weaver W.D., Reisman M.A., Griffin J.J., et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1) a randomised trial . Lancet. 355:2000;2199-2203.
17. Rinfret S., Grines C.L., Cosgrove R.S., et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction one-year results from the Stent-PAMI trial . J Am Coll Cardiol. 38:2001;1614-1621.
18. van Hout B.A., Lindeboom W.K., Morice M.C., et al. Cost-effectiveness of the sirolimus eluting bx-VELOCITY stent 1-year results . Eur Heart J. 23:(Suppl):2002;691.
19. Cohen D.J., Taira D.A., Berezin R., et al. Cost-effectiveness of coronary stenting in acute myocardial infarction results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial . Circulation. 104:2001;3039-3045.
20. Cohen D.J., Bakhai A., Shi C., et al. Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses results from the randomized SIRIUS trial . (abstr) J Am Coll Cardiol. 41:(Suppl):2003;32A.
21. Cohen D.J., Cosgrove R.S., Berezin R.H., et al. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting results from the ESPRIT trial . (abstr) Circulation. 104:(Suppl I):2001;386-387.
22. Reynolds M.R., Neil N., Ho K.K., et al. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery a single-center U.S . experience. Am Heart J. 145:2003;334-342.
23. Cohen D.J., Cosgrove R.S., Berezin R.H., Teirstein P.S., Leon M.B., Kuntz R.E. Cost-effectiveness of gamma radiation for treatment of in-stent restenosis results from the Gamma-1 trial . Circulation. 106:2002;691-697.
24. Clark M.A., Bakhai A., Lacey M., Pelletier E., Cohen D.J. The clinical and economic burden of restenosis in the Medicare population. (abstracts of the 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, October 13-14, 2002, Washington, DC) Circulation. 106:2002;76e-123e.
25. Cohen D.J., O'Shea J.C., Pacchiana C.M., et al. In-hospital costs of coronary stent implantation with and without eptifibatide the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Trial (ESPRIT) . Am J Cardiol. 89:2002;61-64.
26. Gold M., Siegel J., Russel L., Weinstein M. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York, NY.
27. Weinstein M.C., Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 296:1977;716-721.
28. Goldman L., Gordon D.J., Rifkind B.M., et al. Cost and health implications of cholesterol lowering. Circulation. 85:1992;1960-1968.
29. Greenberg D., Cohen D.J. Examining the economic impact of restenosis implications for the cost-effectiveness of an antiproliferative stent . Z Kardiol. 91:2002;137-143.
30. Greenberg D., Bakhai A., Neil N., et al. Modeling the impact of patient and lesion characteristics on the cost-effectiveness of drug-eluting stents. (abstr) J Am Coll Cardiol. 41:(Suppl):2003;538A.
31. Cutlip D.E., Chauhan M.S., Baim D.S., et al. Clinical restenosis after coronary stenting perspectives from multicenter clinical trials . J Am Coll Cardiol. 40:2002;2082-2089.
32. Holmes D.R. Jr., Savage M., LaBlanche J.M., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 106:2002;1243-1250.
33. Serruys P.W., Kay I.P., Disco C., Deshpande N.V., de Feyter P.J. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months results of a meta-analysis of the BElgian NEtherlands STENT study (BENESTENT) I, BENESTENT II pilot, BENESTENT II and Multicenter Ultrasound Stent In Coronaries (MUSIC) trials . J Am Coll Cardiol. 34:1999;1067-1074.
34. Kong DF, Eisenstein EL, Sketch MH, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J 2004. In Press.